Nanobiotix Profit Margin

The latest profit margin for NBTX is -606.12% as of December 2025. That compares with -106.87% in the prior-year period — down 467.1% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Nanobiotix's historical trend and sector peers before judging valuation or financial health.

Over the past year, NBTX's profit margin moved from -106.87% to -606.12% — a 467.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nanobiotix's valuation or profitability profile.

Against Healthcare companies, NBTX currently prints -606.12% for profit margin, while the sector average sits near 14.34%. That is roughly 4325.4% below the sector mean. Large gaps often invite a closer look at Nanobiotix's growth, margins, and balance sheet.

Profit Margin shows how effectively Nanobiotix converts resources into returns. At -606.12%, NBTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -106.87% in the prior-year period — down 467.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NBTX's profit margin (-606.12%), review year-over-year change from -106.87%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.